Drugs / GW501516
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00158899 | Aug 2004 → Jun 2006 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00841217 Comparator | Apr 2003 → Aug 2005 | cardiovascular disorder, lip disorder, obesity disorder | The University of Western Australia | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW501516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00158899 ↗ |
| Known as | Cardarine | ChEMBL registry synonym — accepted as the source's own label CHEMBL38943 ↗ |
| Known as | GSK-516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38943 ↗ |
| Known as | GW-1516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38943 ↗ |
| Action | Activate | “GW501516, a PPAR-δ agonist” PMID 21816786 ↗ Aug 2011 |
| Modality | Small molecule | — CHEMBL38943 ↗ |
| Route | Oral | “GW501516 oral tablets” NCT00158899 ↗ |
| Target | PPARD | “GW501516, a PPAR-δ agonist” PMID 21816786 ↗ Aug 2011 |